Man looking up
Woman looking up
Woman looking up

Clearance Rates

ZORYVE delivered proven and rapid results

See the results at Week 8

Primary
Endpoint

IGA Success*

Key Secondary
Endpoint

I-IGA Success

~40% of patients achieved IGA Success at Week 8

(clear/almost clear + ≥2-grade improvement)‡1,3

ZORYVE(n=286)Vehicle(n=153)WEEK 2WEEK 4WEEK 6WEEK 8DERMIS-16%20%§32%§42%§3%2%6%6%
ZORYVE(n=290)Vehicle(n=152)WEEK 2WEEK 4WEEK 6WEEK 8DERMIS-23%19%§26%§37%§6%2%5%7%
ZORYVE(n=286)Vehicle(n=153)ZORYVE(n=290)Vehicle(n=152)WEEK 2WEEK 4WEEK 6WEEK 8WEEK 2WEEK 4WEEK 6WEEK 8DERMIS-1DERMIS-2§P<0.0001 vs vehicle.6%20%§32%§42%§3%19%§26%§37%§3%2%6%6%6%2%5%7%

§P<0.0001 vs vehicle.

Only Week 8 timepoint is included in the Prescribing Information

IGA Success rates at Week 8 were consistent regardless of baseline involvement

(mild, moderate, severe)‡3

~60% mean PASI improvement at just 8 weeks‡3

*IGA Success = clear/almost clear and a ≥2-grade improvement from baseline.

I-IGA Success = clear/almost clear and a ≥2-grade improvement from baseline in intertriginous areas of the body.

Data from additional prespecified efficacy analyses from the DERMIS-1 and DERMIS-2 trials. These data are not in the Prescribing Information for ZORYVE.

PASI = Psoriasis Area and Severity Index

~70% of patients achieved I-IGA Success at Week 8

(clear/almost clear + ≥2-grade improvement)‡1,3

ZORYVE(n=63)Vehicle(n=32)WEEK 2WEEK 4WEEK 6WEEK 8DERMIS-172%ǁ58%§42%34%28%13%23%14%
ZORYVE(n=53)Vehicle(n=31)WEEK 2WEEK 4WEEK 6WEEK 8DERMIS-233%16%7%13%17%68%ǁ58%53%
§P=0.0001 vs vehicle.ǁP<0.0001 vs vehicle.P<0.01 vs vehicle.ZORYVE(n=63)Vehicle(n=32)ZORYVE(n=53)Vehicle(n=31)WEEK 2WEEK 4WEEK 6WEEK 8WEEK 2WEEK 4WEEK 6WEEK 8DERMIS-1DERMIS-268%ǁ58%53%33%72%ǁ58%§42%34%28%13%23%14%16%7%13%17%

§P=0.0001 vs vehicle.
ǁP<0.0001 vs vehicle.
P<0.01 vs vehicle.

Only Week 8 timepoint is included in the Prescribing Information

Did you know?Did you know?

Clinical trials for ZORYVE were the first and only Phase 3 trials to evaluate I-IGA Success with topical therapy for plaque psoriasis.

*IGA Success = clear/almost clear and a ≥2-grade improvement from baseline.

I-IGA Success = clear/almost clear and a ≥2-grade improvement from baseline in intertriginous areas of the body.

Data from additional prespecified efficacy analyses from the DERMIS-1 and DERMIS-2 trials. These data are not in the Prescribing Information for ZORYVE.